Journal List > Korean J Clin Microbiol > v.15(4) > 1038255

TOOLS
Kim, Park, Lee, Chang, Lee, and Shin: Evaluation of the AdvanSure MDR-TB GenoBlot Assay for Detection of Rifampin and Isoniazid Resistant Mycobacterium tuberculosis Complex in Respiratory Specimens
Original Article
Korean Journal of Clinical Microbiology

Korean Journal of Clinical Microbiology 2012; 15(4): 117-124.

Published online: 21 December 2012

DOI: https://doi.org/10.5145/KJCM.2012.15.4.117

Evaluation of the AdvanSure MDR-TB GenoBlot Assay for Detection of Rifampin and Isoniazid Resistant Mycobacterium tuberculosis Complex in Respiratory Specimens

Jayoung Kim1, Yeon-Joon Park1, Nam Yong Lee2, Chulhun L. Chang3, Miae Lee4, Jong Hee Shin5

1Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.

2Department of Laboratory Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

3Department of Laboratory Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea.

4Department of Laboratory Medicine, Ewha Womans University Mokdong Hospital, Seoul, Korea.

5Department of Laboratory Medicine, Chonnam National University Medical School, Gwangju, Korea.

Correspondence: Yeon-Joon Park, Department of Laboratory Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, 505, Banpo-dong, Seocho-gu, Seoul 137-701, Korea. (Tel) 82-2-2258-1640, (Fax) 82-2-2258-1719, yjpk@catholic.ac.kr

Received 31 May 2012       Revised 17 September 2012       Accepted 19 September 2012

Copyright © 2012 The Korean Society of Clinical Microbiology

Abstract

Background

We evaluated the performance of the AdvanSure MDR-TB GenoBlot Assay kit (AdvanSure MDR-TB, LG Life Science, Korea) to detect mutations related to rifampin (RFP)- and isoniazid (INH)-resistant Mycobacterium tuberculosis complex in respiratory specimens.

Methods

From February 2010 to June 2010, a total of 542 M. tuberculosis clinical isolates were collected from pulmonary tuberculosis patients in six university hospitals across Korea. We analyzed the conventional drug susceptibility testing (DST) and compared the results with those of the AdvanSure MDR-TB.

Results

Compared with the conventional DST, the overall agreement rates, sensitivity, and specificity were 98.2% (532/542), 84.6% (33/39), and 99.2% (499/503), respectively, for RFP resistance and 96.1% (521/542), 79.7% (59/74), 98.7% (462/468), respectively, for INH resistance. The three common rpoB mutations were rpoB S531L (53.8%), rpoB D516V (15.4%) and rpoB H526R (7.7%) in RFP-resistant strains. For INH resistance, the katG S315T mutation (58.1%) was the most common, followed by inhA C-15T (23.0%) and katG S315N (4.1%).

Conclusion

The AdvanSure MDR-TB showed high concordance with the conventional DST and would be helpful for early detection of RFP and INH resistance, although it requires improved sensitivity.

Keywords: AdvanSure MDR-TB, Isoniazid, Mycobacterium tuberculosis, Rifampin

Figures and Tables

Table 1
Agreement rates between the conventional drug susceptibility test and AdvanSure MDR-TB
kjcm-15-117-i001

Abbreviations: RFP, rifampin; INH, isoniazid; DST, the conventional drug susceptibility test; R, resistant; S, susceptible.

Table 2
Discrepant findings of the four methods
kjcm-15-117-i002

Abbreviations: DST, the conventional drug susceptibility test; R, resistant; S, susceptible; r, low level resistance; WT, wild type; -, not tested.

Table 3
Frequencies of mutations associated with RFP by AdvanSure MDR-TB or sequencing
kjcm-15-117-i003

Abbreviations: DST, the conventional drug susceptibility test; New, newly treated patient; Treated, previously treated patient.

Table 4
Frequencies of mutations associated with INH by AdvanSure MDR-TB or sequencing
kjcm-15-117-i004

Abbreviations: DST, the conventional drug susceptibility test; New, newly treated patient; Treated, previously treated patient.

References

1. Kim BJ, Lee IH, Lee DH, Bai GH, Kong SJ, Lee SH, et al. The current status of multidrug-resistant tuberculosis in Korea. Tuberc Respir Dis. 2006. 60:404–411.
2. Korea Centers for Disease Control and Prevention. Annual report on the notified tuberculosis patients in Korea 2009. 2010. Seoul: Korea Centers for Disease Control and Prevention.
3. World Health Organization. Guidelines for the programmatic management of drug resistant tuberculosis: Emergency update 2008. 2008. Geneva, Switzerland: World Health Organization.
4. Joint Committee for the Development of Korean Guidelines for Tuberculosis. Korean guidelines for tuberculosis. 2011. 1st ed. Chungbuk: Korea Centers for Disease Control and Prevention;32–33.
5. Ahmad S, Mokaddas E. Recent advances in the diagnosis and treatment of multidrug-resistant tuberculosis. Respir Med. 2009. 103:1777–1790.
6. Zhang M, Yue J, Yang YP, Zhang HM, Lei JQ, Jin RL, et al. Detection of mutations associated with isoniazid resistance in Mycobacterium tuberculosis isolates from China. J Clin Microbiol. 2005. 43:5477–5482.
7. Kiepiela P, Bishop KS, Smith AN, Roux L, York DF. Genomic mutations in the katG, inhA and aphC genes are useful for the prediction of isoniazid resistance in Mycobacterium tuberculosis isolates from Kwazulu Natal, South Africa. Tuber Lung Dis. 2000. 80:47–56.
8. Akpaka PE, Baboolal S, Clarke D, Francis L, Rastogi N. Evaluation of methods for rapid detection of resistance to isoniazid and rifampin in Mycobacterium tuberculosis isolates collected in the Caribbean. J Clin Microbiol. 2008. 46:3426–3428.
9. Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: part II. Active tuberculosis and drug resistance. Expert Rev Mol Diagn. 2006. 6:423–432.
10. Cho EH, Bae HK, Kang SK, Lee EH. Detection of isoniazid and rifampicin resistance by sequencing of katG, inhA, and rpoB genes in Korea. Korean J Lab Med. 2009. 29:455–460.
11. Jeong TD, An D, Sung H, Chi HS, Kim MN, Shim TS. Evaluation of the performance of GenoType® MTBDRplus assay for rapid detection of multi-drug resistant Mycobacterium tuberculosis in sputum specimens. Lab Med Online. 2011. 1:19–25.
12. Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, et al. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. Global trends in resistance to antituberculosis drugs. N Engl J Med. 2001. 344:1294–1303.
13. Han SB, Jo Y, Yu JK, Kim Y, Park YJ. Performance assessment of AdvanSure™ MDR-TB genoblot assay kit for anti-tuberculosis drug susceptibility test. Lab Med Online. 2012. 2:34–40.
14. Jin J, Zhang Y, Fan X, Diao N, Shao L, Wang F, et al. Evaluation of the GenoType® MTBDRplus assay and identification of a rare mutation for improving MDR-TB detection. Int J Tuberc Lung Dis. 2012. 16:521–526.
15. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet. 1993. 341:647–650.
16. Zaczek A, Brzostek A, Augustynowicz-Kopec E, Zwolska Z, Dziadek J. Genetic evaluation of relationship between mutations in rpoB and resistance of Mycobacterium tuberculosis to rifampin. BMC Microbiol. 2009. 9:10.
17. Hazbón MH, Brimacombe M, Bobadilla del Valle M, Cavatore M, Guerrero MI, Varma-Basil M, et al. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2006. 50:2640–2649.
18. Kim SY, Park YJ, Kim WI, Lee SH, Ludgerus Chang C, Kang SJ, et al. Molecular analysis of isoniazid resistance in Mycobacterium tuberculosis isolates recovered from South Korea. Diagn Microbiol Infect Dis. 2003. 47:497–502.
19. Abe C, Kobayashi I, Mitarai S, Wada M, Kawabe Y, Takashima T, et al. Biological and molecular characteristics of Mycobacterium tuberculosis clinical isolates with low-level resistance to isoniazid in Japan. J Clin Microbiol. 2008. 46:2263–2268.
20. Rinder H, Mieskes KT, Löscher T. Heteroresistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2001. 5:339–345.
21. Kim BJ, Oh SH, Cho EJ, Park SK. Cross-resistance between rifampicin and rifabutin and its relationship with rpoB gene mutations in clinically isolated MDR-TB strains. Tuberc Respir Dis. 2006. 60:171–179.
22. Lin HH, Kim HY, Yun YJ, Park CG, Kim BJ, Park YG, et al. Mutations of katG and inhA in MDR M. tuberculosis. Tuberc Respir Dis. 2007. 63:128–138.
TOOLS
Similar articles